All In Biotech

Drug Trial Radar · NCT04175431

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 30, 2020

Primary completion

Jul 1, 2032

Study completion Jul 1, 2037

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Blue Earth Diagnostics
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.

Conditions

  • Prostate Adenocarcinoma

Interventions

  • Positron Emission TomographyProcedure

    Undergo fluciclovine PET/CT

  • LymphadenectomyProcedure

    Undergo lymphadenectomy

  • Radiation TherapyRadiation

    Undergo radiation therapy

  • Abiraterone AcetateDrug

    Given PO

  • PrednisoneDrug

    Given PO

  • Computed TomographyProcedure

    Undergo fluciclovine PET/CT

  • AbirateroneDrug

    Given PO

  • PSMA PET ScanProcedure

    Undergo PSMA PET scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Undetectable PSA (< 0.2 ng/mL) rateTime frame: At 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania · Recruiting

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.